“We found that men with an elevated FSH but a normal semen test were more likely to have a decline in their sperm concentration and their total motile sperm count over time…when compared to men also starting with the normal semen test but with a normal FSH,” says Joshua Halpern, MD.
“It’s an exciting time in UTUC,” says Joseph Jacob, MD.
“A ureteral stent can be bothersome, but it’s quite variable. Some people don’t even feel the stent and some people have severe symptoms,” says Johnathan Harper, MD.
Investigators reported that all responders had FGFR3 mutations and that most non-responders had a prior history of bladder cancer, with 1 patient having a FGFR3-TACC3 fusion.
“These findings are hypothesis-generating and suggest a possible therapeutically synergistic role for immune checkpoint blockade in [patients with] BCG-unresponsive NMIBC who may have partial or short-term response to nadofaragene treatment,” said lead study author Anirban P. Mitra, MD, PhD.
“[Mitomycin gel] is efficacious as a [chemoablation] agent in adult patients with low-grade upper tract urothelial cancer, and while it’s FDA approved for both antegrade and retrograde administration, prior reports are limited to the retrograde experience,” said study investigator Kyle Rose, MD.
The neoadjuvant combination of the PD-1 inhibitor tislelizumab and nab-paclitaxel induced a high rate of pathologic complete response in patients with muscle-invasive bladder cancer.
The investigators report that no device or procedure-related serious adverse events have occurred.
Treatment with the temporary implantable nitinol device led to a marked reduction in symptoms and improvement in quality of life and functional parameters.
“With proper training and proper technique, there really can be drastic changes that can be made without having to do a surgical intervention,” commented first author Alissa Tyler, RN.
Concurrent treatment with intravenous vitamin C and chemotherapy may benefit cisplatin-ineligible patients with locally advanced muscle-invasive bladder cancer.
Katie Murray, DO, discusses findings from a real-world study of antegrade administration of reverse thermal mitomycin gel for primary chemoablation of upper tract urothelial carcinoma via percutaneous nephrostomy tube.
The hematuria monitor (HM) was discussed in a late-breaking abstract at the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana.
At 2, 3, and 5 weeks after surgery, the stone removal rate was higher in the test group vs the control group (P < .05).
Neoadjuvant axitinib facilitated partial nephrectomy in patients with an imperative indication for nephron-sparing surgery but no viable strategy to receive the procedure.
“Our results showed significant improvement in postoperative urgency and UUI (P = .005) with no significant change in IIEF-5 score at 6-month follow-up compared to baseline,” wrote the authors.
The IELT significantly increased by 3.22-fold in the Mini-patch device group, compared with the sham group (P = .0047).
“This study demonstrates the superiority of the SP in patient-reported cosmetic and pain outcomes on short- and long-term follow-up after uro-oncological surgical procedures,” the study authors concluded.
“Though septic stones are well recognized as a medical emergency, patients with uncomplicated renal colic (without systemic inflammatory responses or renal impairment) and positive urine cultures pose a dilemma in management considerations,” the investigators explained in their abstract.
“HoLEP had a greater uroflowmetry improvement compared to open adenomectomy and TURP,” the investigators concluded. “The mean hospital stay and postoperative catheterization days were reduced compared to open adenomectomy, but there were no differences in this aspect with TURP.”
“SWIU has just, in my humble opinion, gained incredible traction in the last few years, and it's a really great organization,” says Kara L. Watts, MD.
The OS was significantly longer in the avelumab plus BSC vs BSC alone arm in all randomized patients, as well as in patients with PD-L1-positive tumors.
Adjuvant nivolumab continued to demonstrate a clinically meaningful disease-free survival benefit in patients with high-risk, muscle-invasive urothelial carcinoma, according to extended follow-up from the phase 3 CheckMate 274 trial.
“I think this represents an entirely new way of treating bladder cancer,” says William C. Huang, MD.
At a median follow-up of 20.7 months in patients with papillary disease (n = 77), the median DFS was 23.6 months.
Immune-related adverse events may be a prognostic marker for improved survival and progression-free outcomes with pembrolizumab in patients with metastatic urothelial carcinoma.
"A single dose of URO-902 24 mg or 48 mg was associated with clinically relevant improvement in efficacy and quality of life and was safe and well tolerated," says Kenneth M. Peters, MD.
“From our standpoint, bigger prostates bleed more…From that, we started taking a different approach for those larger prostates,” says Andrew Higgins, MD.
"If you look at men who had sexual dysfunction at the beginning of the study, compared to men that had good sexual function at the beginning of a study, both groups of men have equal response to improvement in their lower urinary tract symptoms,” says Kevin T. McVary, MD, FACS.
“The idea that Aquablation [treats] any size and any shape of prostate really does seem to hold true for these cohorts of patients,” says Dean Elterman, MD, MSc, FRCSC.
